Abstract OT1-04-04: EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

2020 ◽  
Author(s):  
Philippe Aftimos ◽  
Aditya Bardia ◽  
Virginia G Kaklamani ◽  
Janice Lu ◽  
Teeru Bihani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Inhibitor Therapy ◽  
Advanced Breast ◽  
Efficacy And Safety ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

2014 ◽  
Vol 15 (7) ◽  
pp. 689-699 ◽  
Author(s):  
Ian E Krop ◽  
Sung-Bae Kim ◽  
Antonio González-Martín ◽  
Patricia M LoRusso ◽  
Jean-Marc Ferrero ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Versus Treatment

Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2– Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial

2018 ◽  
Vol 18 (2) ◽  
pp. e197-e203 ◽  
Author(s):  
Tamar Safra ◽  
Bella Kaufman ◽  
Luna Kadouri ◽  
Noa Efrat (Ben-Baruch) ◽  
Larisa Ryvo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Breast ◽  
Open Label ◽  
Open Label Phase

Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.

2002 ◽  
pp. 267-276 ◽  
Author(s):  
C Morris ◽  
A Wakeling
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Metastatic Breast Cancer ◽  
Advanced Breast Cancer ◽  
Postmenopausal Women ◽  
Endocrine Therapy ◽  
Metastatic Breast ◽  
Advanced Breast ◽  
Phase Iii ◽  
Hormone Receptor Positive

Since its introduction more than 30 years ago, tamoxifen has been the most widely used endocrine therapy for the treatment of women with advanced breast cancer. More recently, a number of alternative endocrine treatments have been developed, including several selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and, most recently, fulvestrant ('Faslodex'). Fulvestrant is an estrogen receptor (ER) antagonist, which, unlike the SERMs, has no known agonist (estrogenic) effect and downregulates the ER protein. Tamoxifen is effective and well tolerated, although the non-steroidal AIs, anastrozole and letrozole, are more effective treatments for advanced disease than tamoxifen. Fulvestrant has recently gained US Food and Drug Administration approval for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. In two global phase III clinical trials fulvestrant was at least as effective and as equally well tolerated as anastrozole for the treatment of postmenopausal women with advanced and metastatic breast cancer. In a retrospective analysis of the combined data from these trials, mean duration of response was significantly greater for fulvestrant compared with anastrozole. These new hormonal treatments expand the choice of endocrine therapy for women with advanced breast cancer and offer new options for sequencing and combining treatments.

Sign in / Sign up

Export Citation Format

Share Document